Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Net Income (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Net Income for 7 consecutive years, with $244.3 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 370.38% to $244.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$80.1 million through Dec 2025, up 78.36% year-over-year, with the annual reading at -$80.0 million for FY2025, 78.77% up from the prior year.
  • Net Income for Q4 2025 was $244.3 million at Beam Therapeutics, up from -$112.7 million in the prior quarter.
  • The five-year high for Net Income was $244.3 million in Q4 2025, with the low at -$200.4 million in Q1 2021.
  • Average Net Income over 5 years is -$60.3 million, with a median of -$86.5 million recorded in 2022.
  • The sharpest move saw Net Income tumbled 621.93% in 2021, then surged 472.37% in 2023.
  • Over 5 years, Net Income stood at -$64.7 million in 2021, then soared by 40.75% to -$38.3 million in 2022, then soared by 472.37% to $142.8 million in 2023, then plummeted by 163.29% to -$90.4 million in 2024, then skyrocketed by 370.38% to $244.3 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at $244.3 million, -$112.7 million, and -$102.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.